Sarah Cannon Research Institute has recruited a veteran of the pharmaceutical development industry to lead its SCRI Services business, which runs clinical research focused on early-phase cancer drugs.
Cindy Perettie comes to SCRI from Roche/Genentech, where she was vice president of regulatory documentation and operations. Before that, she was life cycle leader for Avastin and headed up Genentech’s development work in Europe, the Middle East and Africa.
“Cindy brings over two decades of global drug development experience in clinical development and operations from the pharmaceutical and healthcare industry,” SCRI CEO Dee Anna Smith said. “Her executive leadership will help us continue to enhance our service offering and further our mission of advancing therapies for patients.”
Perettie holds a bachelor’s degree in biochemistry from State University of New York and an MBA from St. Mary’s College. She is involved with a number of industry associations, among them as chairman of the BIO Pharmacovigilance Group.
SCRI, which is a joint venture between HCA Holdings and Tennessee Oncology, works with more than 700 doctors in the United States and United Kingdom. The company recently committed to leasing 150,000 square feet in one of the West End Summit towers Alex S. Palmer & Co. has planned for West End Avenue.